Evidence map›Paper›PMID 41987310›Full record

ArticleJournal of cheminformatics2026

CReM-pharm: de novo 3D pharmacophore-based design with synthetic accessibility awareness.

Alina Denzler, Dinesh Kumar Sriramulu, Jozef Pecha, Pavel Polishchuk

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alina DenzlerInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská, 1333/5, 779 00, Olomouc, Czech Republic.
Dinesh Kumar SriramuluInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská, 1333/5, 779 00, Olomouc, Czech Republic.
Jozef PechaInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská, 1333/5, 779 00, Olomouc, Czech Republic.
Pavel PolishchukInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská, 1333/5, 779 00, Olomouc, Czech Republic. pavlo.polishchuk@upol.cz.

Funding

Ministerstvo Školství, Mládeže a Tělovýchovy LUAUS23262
6 · The paper itself

Abstract

De novo design methodologies have the potential to significantly enhance the exploration of chemical space in the search for promising ligands featuring novel chemotypes. This exploration can be directed through various computational strategies. 3D pharmacophore models, which represent the interaction patterns critical for protein-ligand recognition, can serve as valuable tools for the design of novel compounds. A common limitation of many generative approaches is the low synthetic feasibility of the generated molecular structures. In the present study, we developed a method capable of controllably generating compounds with a relatively high degree of synthetic accessibility by leveraging the CReM framework, while explicitly conforming to a specified 3D pharmacophore model. Evaluation of this approach across a diverse set of protein targets and pharmacophore models of varying complexity demonstrated its effectiveness and highlighted its advantages over the PGMG method, which employs a deep neural network architecture to generate ligands that may exhibit desired 3D geometries upon embedding. The proposed method has been implemented as an open-source tool, CReM-pharm, available at https://github.com/ci-lab-cz/crem-pharm .

Indexed as

3D pharmacophoresDe novo designSynthetic accessibility

Identifiers

PMID41987310
PMCPMC13217670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.